Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
The information required in the remainder of this cover
page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).
|
|
|
|
|
|
|
1.
|
|
Names of
reporting persons
BB Biotech AG
|
2.
|
|
Check the appropriate box if a member
of a group (see instructions)
(a)
x
(b)
¨
|
3.
|
|
SEC use only
|
4.
|
|
Citizenship or place of
organization
Switzerland
|
Number of
shares
beneficially
owned by
each
reporting
person
with:
|
|
5.
|
|
Sole voting power
0
|
|
6.
|
|
Shared voting power
6,271,564
|
|
7.
|
|
Sole dispositive power
0
|
|
8.
|
|
Shared dispositive power
6,271,564
|
9.
|
|
Aggregate amount beneficially owned by each reporting person
6,271,564
|
10.
|
|
Check if the aggregate amount in Row
(9) excludes certain shares
¨
|
11.
|
|
Percent of class represented by amount
in Row (9)
5.0%
|
12.
|
|
Type of reporting person (see
instructions)
HC,CO
|
2 of 7
|
|
|
|
|
|
|
1.
|
|
Names of
reporting persons
Biotech Target N.V.
I.R.S. Identification Nos. of above persons (entities only):
N/A
|
2.
|
|
Check the appropriate box if a member
of a group (see instructions)
(a)
x
(b)
¨
|
3.
|
|
SEC use only
|
4.
|
|
Citizenship or place of
organization
Curacao
|
Number of
shares
beneficially
owned by
each
reporting
person
with:
|
|
5.
|
|
Sole voting power
0
|
|
6.
|
|
Shared voting power
6,271,564
|
|
7.
|
|
Sole dispositive power
0
|
|
8.
|
|
Shared dispositive power
6,271,564
|
9.
|
|
Aggregate amount beneficially owned by each reporting person
6,271,564
|
10.
|
|
Check if the aggregate amount in Row
(9) excludes certain shares
¨
|
11.
|
|
Percent of class represented by amount
in Row (9)
5.0%
|
12.
|
|
Type of reporting person (see
instructions)
CO
|
3 of 7
Item 1
1(a) Name of Issuer:
Halozyme Therapeutics, Inc.
1(b) Address of Issuers Principal Executive Offices:
11388 Sorrento Valley Road, San Diego, CA 92121
Item 2
2(a) Name of Person
Filing:
BB Biotech AG (BB Biotech) on behalf of its wholly-owned subsidiary, Biotech Target N.V. (Biotech Target)
2(b) Address of Principal Business Office or, if none, Residence:
BB Biotech AG: Vordergasse 3, CH-8200 Schaffhausen, Switzerland
Biotech Target N.V.: Snipweg 26, Curacao
2(c) Citizenship:
BB Biotech AG: Switzerland
Biotech Target N.V.: Curacao
2(d) Title of Class of Securities
Common Stock, $0.001 par value
2(e) CUSIP Number
40637H109
Item 3
If this statement is filed pursuant to
Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
a.
¨
Broker or Dealer registered under Section 15 of the Act.
b.
¨
Bank as defined in Section 3(a)(6) of the Act.
c.
¨
Insurance company as defined in Section 3(a)(19) of the Act.
d.
¨
Investment company registered under section 8 of the Investment Company Act of 1940.
e.
¨
An investment adviser in accordance with Rule
13d-1(b)(1)(ii)(E);
f.
¨
An
employee benefit plan or endowment fund in accordance with Rule
13d-1(b)(1)(ii)(F);
g.
¨
A parent holding company or control person in accordance with Rule
13d-1(b)(1)(ii)(G);
h.
¨
A savings associations as defined in Section 3(b) of the Federal
Deposit Insurance Act (12 U.S.C. 1813);
i.
¨
A church plan that is
excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
j.
¨
Group, in accordance with Rule
13d-1(b)(1)(ii)(J).
4 of 7
Item 4. Ownership
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in
Item 1.
(a) Amount beneficially owned:
6,271,564
(b) Percent of class:
5.0%
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote
0
(ii) Shared power to vote or to direct the vote
6,271,564
(iii) Sole power to dispose or to direct the disposition of
0
(iv) Shared power to dispose or to direct the disposition of
6,271,564
Item 5. Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of
more than five percent of the class of securities, check the following:
¨
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
N/A
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
This statement is filed jointly by BB Biotech and Biotech Target, Biotech Target is a wholly-owned subsidiary of BB Biotech.
Item 8. Identification and Classification of Members of the Group
N/A
Item 9. Notice of
Dissolution of Group
N/A
5 of 7
Item 10. Certification
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held
for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
SIGNATURES
After reasonable inquiry and
the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
BB Biotech
AG
|
|
|
|
|
|
|
|
|
Date:
|
|
August 6, 2014
|
|
|
|
By:
|
|
/s/ Daniel
Koller
|
|
|
|
|
|
|
|
|
Signatory Authority
|
|
|
|
|
|
|
|
|
|
|
|
Name:
|
|
Daniel Koller
|
|
|
|
|
|
|
|
|
|
|
|
Title:
|
|
Signatory Authority
|
|
|
|
|
|
Date:
|
|
August 6, 2014
|
|
|
|
By:
|
|
/s/ Ivo
Betschart
|
|
|
|
|
|
|
|
|
Signatory Authority
|
|
|
|
|
|
|
|
|
|
|
|
Name:
|
|
Ivo Betschart
|
|
|
|
|
|
|
|
|
|
|
|
Title:
|
|
Signatory Authority
|
|
|
|
|
Biotech Target N.V.
|
|
|
|
|
|
|
|
|
|
|
|
Date:
|
|
August 6, 2014
|
|
|
|
By:
|
|
/s/ Daniel
Koller
|
|
|
|
|
|
|
|
|
Signatory Authority
|
|
|
|
|
|
|
|
|
|
|
|
Name:
|
|
Daniel Koller
|
|
|
|
|
|
|
|
|
|
|
|
Title:
|
|
Signatory Authority
|
|
|
|
|
|
Date:
|
|
August 6, 2014
|
|
|
|
By:
|
|
/s/ Ivo
Betschart
|
|
|
|
|
|
|
|
|
Signatory Authority
|
|
|
|
|
|
|
|
|
|
|
|
Name:
|
|
Ivo Betschart
|
|
|
|
|
|
|
|
|
|
|
|
Title:
|
|
Signatory Authority
|
6 of 7
Exhibit A
Joint Filing Statement
We, the undersigned, hereby express our agreement that the attached Schedule 13G (including all amendments thereto) is filed on behalf of each
of the undersigned.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BB Biotech AG
|
|
|
|
|
|
Date:
|
|
August 6, 2014
|
|
|
|
By:
|
|
/s/ Daniel
Koller
|
|
|
|
|
|
|
|
|
Signatory Authority
|
|
|
|
|
|
|
|
|
|
|
|
Name:
|
|
Daniel Koller
|
|
|
|
|
|
|
|
|
|
|
|
Title:
|
|
Signatory Authority
|
|
|
|
|
|
Date:
|
|
August 6, 2014
|
|
|
|
By:
|
|
/s/ Ivo
Betschart
|
|
|
|
|
|
|
|
|
Signatory Authority
|
|
|
|
|
|
|
|
|
|
|
|
Name:
|
|
Ivo Betschart
|
|
|
|
|
|
|
|
|
|
|
|
Title:
|
|
Signatory Authority
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biotech Target N.V.
|
|
|
|
|
|
Date:
|
|
August 6, 2014
|
|
|
|
By:
|
|
/s/ Daniel
Koller
|
|
|
|
|
|
|
|
|
Signatory Authority
|
|
|
|
|
|
|
|
|
|
|
|
Name:
|
|
Daniel Koller
|
|
|
|
|
|
|
|
|
|
|
|
Title:
|
|
Signatory Authority
|
|
|
|
|
|
Date:
|
|
August 6, 2014
|
|
|
|
By:
|
|
/s/ Ivo
Betschart
|
|
|
|
|
|
|
|
|
Signatory Authority
|
|
|
|
|
|
|
|
|
|
|
|
Name:
|
|
Ivo Betschart
|
|
|
|
|
|
|
|
|
|
|
|
Title:
|
|
Signatory Authority
|
7 of 7